<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02123264</url>
  </required_header>
  <id_info>
    <org_study_id>CGV222</org_study_id>
    <nct_id>NCT02123264</nct_id>
  </id_info>
  <brief_title>Zoledronic Acid in Rheumatoid Arthritis</brief_title>
  <acronym>AZAR</acronym>
  <official_title>Randomized Clinical Trial on the Prevention of Radiographic Progression With Zoledronic Acid in Patients With Early Rheumatoid Arthritis and Low Disease Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmen Gómez-Vaquero</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The progression of structural joint damage is the leading cause of disability and
      socioeconomic costs associated with rheumatoid arthritis (RA). Remission and low clinical
      activity not always imply absence of progression of structural damage. The main objective of
      this study is to evaluate the progression of radiological damage in early RA patients
      currently treated with disease modifying anti-rheumatic drugs (DMARDs) and low disease
      activity to which treatment with zoledronic acid is added.

      The investigators propose a randomized clinical trial in 94 patients with RA of less than 2
      years of evolution that, being treated with DMARDs, present criteria of low disease activity
      (DAS28 &lt; 3.2).

      Patients will be randomized into two branches: zoledronic acid and no treatment. The primary
      study endpoint is the progression of radiological damage assessed in a blinded way by the
      difference in the Sharp-van der Heijde index (SHI) in radiographs of hands and feet after two
      years; the secondary variables: radiographic progression after one year, serum bone
      biomarkers (OPG, RANKL, DKK-1 and sclerostin) and adverse effects. In a subgroup of patients,
      the investigators shall evaluate the change in the size of hand erosions by multislice
      computed tomography and the evolution of periarticular osteoporosis and systemic bone mass by
      dual X-ray absorptiometry (DXA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sharp van der Heijde index</measure>
    <time_frame>Two years</time_frame>
    <description>To assess the progression of radiographic damage in patients with early RA in current treatment with DMARDs and low disease activity to which treatment with zoledronic acid is added, compared to a no treatment control population, after two years.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Zoledronic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zoledronic acid: 5 mg/year x 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>Zoledronic acid: 5 mg/year x 2 years</description>
    <arm_group_label>Zoledronic acid</arm_group_label>
    <other_name>Aclasta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age equal or greater than 18 years

          2. Patients with RA of less than 2 years of evolution

          3. DMARD therapy (methotrexate alone or methotrexate, leflunomide or methotrexate within
             COBRA strategy) on stable dose for at least 6 weeks prior to study entry

          4. Patients not treated with glucocorticoids or under stable dose of prednisone up to 5
             mg / day or equivalent dose of another glucocorticoid

          5. Low disease activity (DAS28 &lt;3.2)

          6. In case of premenopausal women, commitment to make contraceptive treatment up to 3
             years after the last dose of zoledronic acid

          7. Signed informed consent

        Exclusion Criteria:

          1. Previous or current treatment with biological drugs used for the treatment of RA
             (infliximab, adalimumab, etanercept, certolizumab, golimumab, rituximab, abatacept,
             tocilizumab)

          2. Pretreatment with:

               1. Bisphosphonates in the 5 years prior to the onset of RA

               2. Calcitonin, raloxifene, bazedoxifene, strontium ranelate, teriparatide and
                  denosumab in the year before the onset of RA

          3. Contraindication to treatment with zoledronic acid:

               1. Hypersensitivity to bisphosphonates

               2. Hypocalcemia

               3. Glomerular filtration rate &lt;35 mL / min

               4. Pregnant (negative pregnancy test) and lactating women

               5. Poor oral hygiene

               6. Pending invasive dental procedure

          4. Serum levels of calcidiol lower than 25 nmol/L (10 ng/mL).

          5. Simultaneous participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Gómez-Vaquero, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvia Pérez-Pujol, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UCICEC-Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carmen Gómez-Vaquero, MD, PhD</last_name>
    <phone>+34932607712</phone>
    <email>carmen.gomez@bellvitgehospital.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Gómez-Vaquero, MD, PhD</last_name>
      <phone>+34 93 2607712</phone>
      <email>carmen.gomez@bellvitgehospital.cat</email>
    </contact>
    <investigator>
      <last_name>Javier Narváez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joan M Nolla, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Antonio Narváez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Hernández-Gañan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Alía, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Joan Despí Moisés Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Roig-Vilaseca, MD, PhD</last_name>
      <phone>34 93 5531200</phone>
      <phone_ext>8523</phone_ext>
      <email>26188drv@comb.cat</email>
    </contact>
    <investigator>
      <last_name>Daniel Roig-Vilaseca, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Residència Sant Camil</name>
      <address>
        <city>Sant Pere de Ribes</city>
        <state>Barcelona</state>
        <zip>08810</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Campoy, MD, PhD</last_name>
      <phone>34 93 8960025</phone>
      <phone_ext>3515</phone_ext>
      <email>ecampoy@csg.cat</email>
    </contact>
    <investigator>
      <last_name>Esther Campoy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Viladecans</name>
      <address>
        <city>Viladecans</city>
        <state>Barcelona</state>
        <zip>08840</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José María Ruiz, MD</last_name>
      <phone>34 93 6590111</phone>
      <phone_ext>251</phone_ext>
      <email>jmruiz.hv@gencat.cat</email>
    </contact>
    <investigator>
      <last_name>José María Ruiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergi Ros, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Bilbao</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joana Atxotegui Saenz de Buruaga, MD</last_name>
      <phone>34 94 6006470</phone>
      <email>joana.atxotegisaenzdeburuaga@osakidetza.net</email>
    </contact>
    <investigator>
      <last_name>Joana Atxotegui Saenz de Buruaga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alberto Alonso, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie Rivas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Fiter, MD</last_name>
      <phone>+34 871205345</phone>
      <email>jordi.fiter@ssib.es</email>
    </contact>
    <investigator>
      <last_name>Jordi Fiter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lluís Espadaler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenaro Graña, MD, PhD</last_name>
      <phone>34 98 1176307</phone>
      <email>genaro.grana.gil@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Jenaro Graña, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier de Toro, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Hernández-Miguel, MD, PhD</last_name>
      <phone>34 93 2275400</phone>
      <phone_ext>2236</phone_ext>
      <email>mvhernan@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Victoria Hernández-Miguel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raimon Sanmartí, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana M Ortiz-García, MD, Phd</last_name>
      <phone>34 91 5202200</phone>
      <phone_ext>2473</phone_ext>
      <email>lanult@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Ana M Ortiz-García, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Nuño, MD, PhD</last_name>
      <phone>34 91 2727108</phone>
      <email>lauranuno2@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Laura Nuño, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pilar Aguado, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blanca Hernández-Cruz, MD, PhD</last_name>
      <phone>34 95 5009124</phone>
      <email>blancahcruz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Blanca Hernández-Cruz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paula Cejas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2014</study_first_posted>
  <last_update_submitted>February 21, 2016</last_update_submitted>
  <last_update_submitted_qc>February 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Carmen Gómez-Vaquero</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

